Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

药代动力学 加药 耐受性 医学 药效学 药理学 人口 内科学 安慰剂 非酒精性脂肪性肝炎 不利影响 脂肪肝 非酒精性脂肪肝 替代医学 疾病 病理 环境卫生
作者
Chih-Ming L. Tseng,Kemal Balic,R. Will Charlton,Maya Margalit,Hank Mansbach,Radojka M. Savić
出处
期刊:Clinical Pharmacology & Therapeutics [Wiley]
卷期号:114 (6): 1323-1331 被引量:2
标识
DOI:10.1002/cpt.3046
摘要

Pegozafermin is a long‐acting glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. In a phase Ib/IIa placebo‐controlled, double‐blind, multiple ascending dose study in patients with NASH (NCT04048135), administration of pegozafermin resulted in clinically meaningful reductions in hepatic fat fraction (HFF), with a favorable safety and tolerability profile. We aimed to characterize the relationship between pegozafermin dosing, exposure and effects on HFF reduction. We used pharmacokinetic (PK) and pharmacodynamic (PD) modeling of data from the phase Ib/IIa study to identify model parameters and covariates affecting the exposure–response relationship. Clinical simulations were performed to help support dose selection for larger studies. Pegozafermin exposure was adequately described by a one compartment PK model, with one additional transit absorption compartment. PK/PD modeling demonstrated that HFF reduction was significantly related to pegozafermin exposure. HFF outcomes were correlated with average pegozafermin concentrations regardless of weekly dosing (q.w.) or dosing every 2 weeks (q2w). The significant PK/PD model covariates included baseline body weight, alanine aminotransferase level, and liver volume. Simulations showed that the 30 mg q.w. dose approximated the full PD effect; almost all patients would benefit from a greater than or equal to 30% HFF reduction, suggesting fibrosis regression. Furthermore, 44 mg q2w dosing (~22 mg q.w.) appeared to be an effective regimen for HFF reduction. Our modeling supports the feasibility of q.w. and q2w dosing for achieving favorable treatment outcomes in patients with NASH, and provides the rationale for dose selection for the phase IIb ENLIVEN study (NCT04929483).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
777发布了新的文献求助10
刚刚
qnqf发布了新的文献求助10
1秒前
深情安青应助tinatian270采纳,获得10
1秒前
天天快乐应助哭泣雅绿采纳,获得10
1秒前
SEASON发布了新的文献求助10
1秒前
犹豫小笼包应助aaz采纳,获得10
1秒前
我是老大应助愤怒的小凝采纳,获得10
1秒前
鱼鱼完成签到,获得积分10
1秒前
liupidanqiu发布了新的文献求助10
2秒前
健忘丹珍完成签到,获得积分10
2秒前
zjl900111完成签到,获得积分10
2秒前
珈蓝发布了新的文献求助10
2秒前
天上的鱼完成签到,获得积分10
2秒前
齐芮发布了新的文献求助10
3秒前
3秒前
SSS完成签到,获得积分20
3秒前
小小完成签到 ,获得积分10
4秒前
4秒前
ZSJ发布了新的文献求助30
5秒前
珂伟完成签到,获得积分10
5秒前
5秒前
5秒前
雨柏完成签到 ,获得积分10
5秒前
zy完成签到,获得积分10
6秒前
西柚完成签到,获得积分10
7秒前
Owen应助LM采纳,获得10
7秒前
8秒前
9秒前
Loy's完成签到,获得积分10
9秒前
ws完成签到,获得积分20
9秒前
张瑞雪发布了新的文献求助10
9秒前
10秒前
10秒前
bkagyin应助琪琪的采纳,获得10
10秒前
10秒前
minisword发布了新的文献求助50
10秒前
11秒前
十四季白完成签到 ,获得积分10
11秒前
11秒前
lxx发布了新的文献求助10
11秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
The Data Economy: Tools and Applications 1000
Diamonds: Properties, Synthesis and Applications 800
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufen 700
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3095922
求助须知:如何正确求助?哪些是违规求助? 2747787
关于积分的说明 7596792
捐赠科研通 2399425
什么是DOI,文献DOI怎么找? 1273033
科研通“疑难数据库(出版商)”最低求助积分说明 615515
版权声明 598948